SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Total Liabilities came in at $21.2 million in Q1 2026, up 26.98% YoY from $16.7 million in Q1 2025, and little changed on a QoQ basis from $21.3 million in Q4 2025.
SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Total Liabilities data on file, last reported at $21.2 million in Q1 2026.
- Quarterly Total Liabilities rose 26.98% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 26.98% YoY) and the FY2025 annual result came in at $21.3 million, up 16.95% from the prior year.
- Total Liabilities was little changed at $21.2 million in Q1 2026, from $21.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $27.2 million in Q1 2022 to a low of $13.1 million in Q3 2023.
- A 5-year average of $19.4 million and a median of $18.4 million in 2025 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 245.4% in 2022, down 53.4% in 2022.
- Tracing SABS's Total Liabilities over 5 years: stood at $19.8 million in 2022, then jumped by 34.24% to $26.6 million in 2023, then slumped by 31.59% to $18.2 million in 2024, then gained by 16.95% to $21.3 million in 2025, then declined by 0.44% to $21.2 million in 2026.
- The last three Total Liabilities figures came in at $21.2 million (Q1 2026), $21.3 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 23.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.43 Mn |
| Mar 31, 2026 | 21.22 Mn |
| Dec 31, 2025 | 21.32 Mn |
| Sep 30, 2025 | 18.37 Mn |
| Jun 30, 2025 | 18.11 Mn |
| Mar 31, 2025 | 16.71 Mn |
| Dec 31, 2024 | 18.23 Mn |
| Sep 30, 2024 | 16.89 Mn |
| Jun 30, 2024 | 15.77 Mn |
| Mar 31, 2024 | 18.55 Mn |
| Dec 31, 2023 | 26.64 Mn |
| Sep 30, 2023 | 13.08 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Mar 31, 2023 | 18.27 Mn |
| Dec 31, 2022 | 19.85 Mn |
| Sep 30, 2022 | 21.88 Mn |
| Jun 30, 2022 | 22.29 Mn |
| Mar 31, 2022 | 27.23 Mn |
| Dec 31, 2021 | 42.59 Mn |
| Sep 30, 2021 | 10.07 Mn |